Seeking Alpha

Arena Pharmaceuticals Inc. (ARNA)

()

News & PR
Market Currents

Buzz
Twitter: ARNA

Business Intelligence
Transcripts
Events
Key Developments

Instablog posts on ARNA

VVUS-Obesity and ED: Two Big Markets, One Tiny Company by Penn Bioinvestor
This article is from minyanville. If the article is right, VVUS obesity drug can reach peak annual sell at $10 billion, ED drug sell at over $1 billion, I would say the fair value of VVUS is >$200/share. Everyone who bought and hold VVUS at today's level will smile even in sleep.... More »
November 27, 2009 • VVUS, OREX, ARNA
Up, Down, Up. Is ARNA a Home Run or Not? by Penn Bioinvestor
A very nice article from Brian Orell at fool.com, well written and right on point: www.fool.com/investing/high-growth/2009/...Shares of Arena Pharmaceuticals (Nasdaq: ARNA) have been on a roller coaster over the past 24 hours. It rose by 38% after hours on word that the company would release... More »
September 20, 2009 • ARNA, VVUS, OREX
Buy The Obesity Drug Basket: ARNA, OREX, VVUS by Michael Murphy
For many years, the Department of Agriculture has published a food triangle that recommends carbohydrates as the basis of a healthy diet, even though there is no minimum daily requirement for carbs. None. Dr. Atkins is rolling over in his grave. Although this has done far more damage to the... More »
September 20, 2009 • ARNA, OREX, VVUS
J. P.Morgan latest analyst report on ARNA by Penn Bioinvestor
J. P.Morgan latest analyst report on ARNA: This morning, Arena (ARNA) released what we consider to be disappointing Phase 3 results from the BLOSSOM obesity trial. Lorcaserin’s efficacy was once again underwhelming – even worse than the prior BLOOM trial – and, indeed, some may... More »
September 18, 2009 • ARNA, VVUS, OREX
Vivus still has good upside potential by Penn Bioinvestor
In the past few days, obesity drug Qnexa being developed by Vivus, Inc. (VVUS) drew quite some attention from mass media. The recent Qnexa Phase III data showed both high efficacy and good safety. There is an important aspect here, and that is that it puts two other drug companies in the hot... More »
September 16, 2009 • VVUS, OREX, ARNA
How to correctly understand the value of VVUS by Penn Bioinvestor
Just find this nice post on internet from goldengatesings2 at Yahoo message board, I would like to share with you guys, happy reading.goldengatesings2 wrote: There have been many posts here that claim that QNexa doesnt have anything and that one could always just take a combination of generic... More »
September 13, 2009 • VVUS, ARNA, OREX
Expect a big day tomorrow for VVUS by Penn Bioinvestor
VVUS rallied in after hour, goes as high as 8.74. The market is expecting some good news tomorrow morning. The efficacy of Qnexa is the best among the three late stage obesity experimental drug, far superior than ARNA and OREX, that will not be any question. The only concern is any major... More »
September 8, 2009 • VVUS, ARNA, OREX
OREX: Cramer Just Now Getting His Toga On, There Is Still Time For You by Ruthanne Williams Roussel
Cramer made a call Thursday night that the FDA will approve Orexigen's (OREX) weight-loss drug Contrave. Hear the call. Cramer's basic summary of the case for obesity drugs is fine, and I agree that Contrave's chances for approval are excellent. But for ages I have been arguing... More »
August 17, 2009 • OREX, VVUS, ARNA
OREX: Cramer Predicts FDA Approval, Won't Stub Toe Like SVNT by Ruthanne Williams Roussel
Cramer has set the stock of Orexigen (OREX) a-percolatin' with his opinion that the FDA will approve its weight-loss drug Contrave. On Tuesday night, he was stumped by a question about this small pharma, and then as he promised, he (and, presumably, his team) did his research and came back... More »
August 14, 2009 • VVUS, OREX, SVNT
Arena Seems to Have Edge in Obesity Drug Race by Beacon Asset Managers
As the U.S. obesity epidemic grows ever bigger–pardon the pun–with aging Baby Boomer and Generation X waistlines expanding and record numbers of obese Gen. Y children burgeoning into adulthood, three companies are vying to become first to market with potential... More »
July 24, 2009 • ARNA, VVUS, OREX

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Arena Pharmaceuticals Inc. (ARNA)

Instablog posts on ARNA

VVUS-Obesity and ED: Two Big Markets, One Tiny Company by Penn Bioinvestor

Up, Down, Up. Is ARNA a Home Run or Not? by Penn Bioinvestor

Buy The Obesity Drug Basket: ARNA, OREX, VVUS by Michael Murphy

J. P.Morgan latest analyst report on ARNA by Penn Bioinvestor

Vivus still has good upside potential by Penn Bioinvestor

How to correctly understand the value of VVUS by Penn Bioinvestor

Expect a big day tomorrow for VVUS by Penn Bioinvestor

OREX: Cramer Just Now Getting His Toga On, There Is Still Time For You by Ruthanne Williams Roussel

OREX: Cramer Predicts FDA Approval, Won't Stub Toe Like SVNT by Ruthanne Williams Roussel

Arena Seems to Have Edge in Obesity Drug Race by Beacon Asset Managers

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers